CA2411386A1 - Therapie de combinaison pour le traitement des psychoses - Google Patents
Therapie de combinaison pour le traitement des psychoses Download PDFInfo
- Publication number
- CA2411386A1 CA2411386A1 CA002411386A CA2411386A CA2411386A1 CA 2411386 A1 CA2411386 A1 CA 2411386A1 CA 002411386 A CA002411386 A CA 002411386A CA 2411386 A CA2411386 A CA 2411386A CA 2411386 A1 CA2411386 A1 CA 2411386A1
- Authority
- CA
- Canada
- Prior art keywords
- thiadiazol
- tetrahydro
- methylpyridine
- component
- azabicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000028017 Psychotic disease Diseases 0.000 title claims abstract description 32
- 238000002648 combination therapy Methods 0.000 title abstract description 5
- 239000003693 atypical antipsychotic agent Substances 0.000 claims abstract description 21
- 229940127236 atypical antipsychotics Drugs 0.000 claims abstract description 20
- 239000000472 muscarinic agonist Substances 0.000 claims abstract description 20
- 230000000561 anti-psychotic effect Effects 0.000 claims abstract description 18
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 23
- 229960005017 olanzapine Drugs 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 229950006755 xanomeline Drugs 0.000 claims description 18
- JOLJIIDDOBNFHW-UHFFFAOYSA-N xanomeline Chemical group CCCCCCOC1=NSN=C1C1=CCCN(C)C1 JOLJIIDDOBNFHW-UHFFFAOYSA-N 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 201000000980 schizophrenia Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 150000001875 compounds Chemical class 0.000 description 34
- 239000000203 mixture Substances 0.000 description 28
- -1 chlorprathixene Chemical compound 0.000 description 27
- 150000003839 salts Chemical class 0.000 description 18
- 230000004044 response Effects 0.000 description 15
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 229910052736 halogen Inorganic materials 0.000 description 9
- 150000002367 halogens Chemical class 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 150000002431 hydrogen Chemical class 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000001143 conditioned effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000005864 Sulphur Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229960001076 chlorpromazine Drugs 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229960002690 fluphenazine Drugs 0.000 description 3
- 229960003878 haloperidol Drugs 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229960001534 risperidone Drugs 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- MHPPLPIQDSLFRZ-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-[3-(4-methylphenyl)propoxy]-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCC1=CC=C(C)C=C1 MHPPLPIQDSLFRZ-UHFFFAOYSA-N 0.000 description 2
- CMPNWGQBNRHIQZ-UHFFFAOYSA-N 3-chloro-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound ClC1=NSN=C1C1=CC=CN=C1 CMPNWGQBNRHIQZ-UHFFFAOYSA-N 0.000 description 2
- VJUYUCDQCJLBOZ-UHFFFAOYSA-N 3-hexoxy-4-pyridin-3-yl-1,2,5-thiadiazole Chemical compound CCCCCCOC1=NSN=C1C1=CC=CN=C1 VJUYUCDQCJLBOZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 2
- 208000020186 Schizophreniform disease Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000011360 adjunctive therapy Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 125000006038 hexenyl group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960000423 loxapine Drugs 0.000 description 2
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960004938 molindone Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 208000002851 paranoid schizophrenia Diseases 0.000 description 2
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- BTFMCMVEUCGQDX-UHFFFAOYSA-N 1-[10-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propyl]-2-phenothiazinyl]ethanone Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 BTFMCMVEUCGQDX-UHFFFAOYSA-N 0.000 description 1
- ODYCHWWAVAJWGC-UHFFFAOYSA-N 1-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]oxy]hexan-3-ol Chemical compound CCCC(O)CCOC1=NSN=C1C1=CCCN(C)C1 ODYCHWWAVAJWGC-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- MSGNNUXHNVASPR-UHFFFAOYSA-N 2-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]oxy]ethylurea Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCNC(N)=O MSGNNUXHNVASPR-UHFFFAOYSA-N 0.000 description 1
- MISVBRCIQTYZPQ-UHFFFAOYSA-N 2-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanyl]acetonitrile Chemical compound C1N(C)CCC=C1C1=NSN=C1SCC#N MISVBRCIQTYZPQ-UHFFFAOYSA-N 0.000 description 1
- SGCPBVKKDRXBIB-UHFFFAOYSA-N 2-amino-2-pyridin-3-ylacetonitrile Chemical compound N#CC(N)C1=CC=CN=C1 SGCPBVKKDRXBIB-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- HMGCGUWFPZVPEK-UHFFFAOYSA-N 2-naphthalen-2-ylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=C1 HMGCGUWFPZVPEK-UHFFFAOYSA-N 0.000 description 1
- PHRFWHDKOILPAW-UHFFFAOYSA-N 3-(1,2,3,6-tetrahydropyridin-5-yl)-4-(2,2,2-trifluoroethoxy)-1,2,5-thiadiazole Chemical compound FC(F)(F)COC1=NSN=C1C1=CCCNC1 PHRFWHDKOILPAW-UHFFFAOYSA-N 0.000 description 1
- MRPSUPHUBCADLS-UHFFFAOYSA-N 3-(1,2-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-4-(3-phenylpropylsulfanyl)-1,2,5-thiadiazole Chemical compound C1N(C)C(C)CC=C1C1=NSN=C1SCCCC1=CC=CC=C1 MRPSUPHUBCADLS-UHFFFAOYSA-N 0.000 description 1
- QVWFMJQZDNOHFC-UHFFFAOYSA-N 3-(1,2-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-4-ethoxy-1,2,5-thiadiazole Chemical compound CCOC1=NSN=C1C1=CCC(C)N(C)C1 QVWFMJQZDNOHFC-UHFFFAOYSA-N 0.000 description 1
- CXHCWCAXJOPYPC-UHFFFAOYSA-N 3-(1,2-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-4-ethylsulfanyl-1,2,5-thiadiazole Chemical compound CCSC1=NSN=C1C1=CCC(C)N(C)C1 CXHCWCAXJOPYPC-UHFFFAOYSA-N 0.000 description 1
- WSGWLVRZLSQAQL-UHFFFAOYSA-N 3-(1,2-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-4-hex-3-ynoxy-1,2,5-thiadiazole Chemical compound CCC#CCCOC1=NSN=C1C1=CCC(C)N(C)C1 WSGWLVRZLSQAQL-UHFFFAOYSA-N 0.000 description 1
- AYKBHKPBCKQZIT-UHFFFAOYSA-N 3-(1,2-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-4-hexoxy-1,2,5-thiadiazole Chemical compound CCCCCCOC1=NSN=C1C1=CCC(C)N(C)C1 AYKBHKPBCKQZIT-UHFFFAOYSA-N 0.000 description 1
- ABYVPNFKIXOLAQ-UHFFFAOYSA-N 3-(1,2-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-4-hexylsulfanyl-1,2,5-thiadiazole Chemical compound CCCCCCSC1=NSN=C1C1=CCC(C)N(C)C1 ABYVPNFKIXOLAQ-UHFFFAOYSA-N 0.000 description 1
- GJLTWMHQWZYFCR-UHFFFAOYSA-N 3-(1,2-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-4-pent-4-enoxy-1,2,5-thiadiazole Chemical compound C1N(C)C(C)CC=C1C1=NSN=C1OCCCC=C GJLTWMHQWZYFCR-UHFFFAOYSA-N 0.000 description 1
- DYCZTUCBGVQCNM-UHFFFAOYSA-N 3-(1,2-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-4-pentoxy-1,2,5-thiadiazole Chemical compound CCCCCOC1=NSN=C1C1=CCC(C)N(C)C1 DYCZTUCBGVQCNM-UHFFFAOYSA-N 0.000 description 1
- WVUCEDBQSONIOD-UHFFFAOYSA-N 3-(1,2-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-4-pentylsulfanyl-1,2,5-thiadiazole Chemical compound CCCCCSC1=NSN=C1C1=CCC(C)N(C)C1 WVUCEDBQSONIOD-UHFFFAOYSA-N 0.000 description 1
- NRCRSNGJOLOBPR-UHFFFAOYSA-N 3-(1,4-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-4-hexoxy-1,2,5-thiadiazole Chemical compound CCCCCCOC1=NSN=C1C1=C(C)CCN(C)C1 NRCRSNGJOLOBPR-UHFFFAOYSA-N 0.000 description 1
- YJXBAFAAZNWUGG-UHFFFAOYSA-N 3-(1,4-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-4-methoxy-1,2,5-thiadiazole Chemical compound COC1=NSN=C1C1=C(C)CCN(C)C1 YJXBAFAAZNWUGG-UHFFFAOYSA-N 0.000 description 1
- JWKLZRFVIDTEJR-UHFFFAOYSA-N 3-(1-ethyl-3,6-dihydro-2h-pyridin-5-yl)-4-ethylsulfanyl-1,2,5-thiadiazole Chemical compound CCSC1=NSN=C1C1=CCCN(CC)C1 JWKLZRFVIDTEJR-UHFFFAOYSA-N 0.000 description 1
- FFHHMEJEQSFFII-UHFFFAOYSA-N 3-(1-ethyl-3,6-dihydro-2h-pyridin-5-yl)-4-hexoxy-1,2,5-thiadiazole Chemical compound CCCCCCOC1=NSN=C1C1=CCCN(CC)C1 FFHHMEJEQSFFII-UHFFFAOYSA-N 0.000 description 1
- LCQRTAAPRPCYPW-UHFFFAOYSA-N 3-(1-ethyl-3,6-dihydro-2h-pyridin-5-yl)-4-hexylsulfanyl-1,2,5-thiadiazole Chemical compound CCCCCCSC1=NSN=C1C1=CCCN(CC)C1 LCQRTAAPRPCYPW-UHFFFAOYSA-N 0.000 description 1
- ZOWIXCHZMIQOIE-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(2,2,2-trifluoroethoxy)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCC(F)(F)F ZOWIXCHZMIQOIE-UHFFFAOYSA-N 0.000 description 1
- JXXJRVBUWHQUTE-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(2,2,2-trifluoroethylsulfanyl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCC(F)(F)F JXXJRVBUWHQUTE-UHFFFAOYSA-N 0.000 description 1
- LYTBTBBCSAHRAY-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(2-methylpropoxy)-1,2,5-thiadiazole Chemical compound CC(C)COC1=NSN=C1C1=CCCN(C)C1 LYTBTBBCSAHRAY-UHFFFAOYSA-N 0.000 description 1
- BPIKEGXWXGFLMR-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(2-phenoxyethylsulfanyl)-1,2,5-oxadiazole Chemical compound C1N(C)CCC=C1C1=NON=C1SCCOC1=CC=CC=C1 BPIKEGXWXGFLMR-UHFFFAOYSA-N 0.000 description 1
- COXDDTLVAWXUPJ-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(2-phenylethoxy)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCC1=CC=CC=C1 COXDDTLVAWXUPJ-UHFFFAOYSA-N 0.000 description 1
- XRIURDSJUBPJQZ-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(2-phenylethylsulfanyl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCC1=CC=CC=C1 XRIURDSJUBPJQZ-UHFFFAOYSA-N 0.000 description 1
- KVMADAPPEILLFV-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(2-propan-2-yloxyethoxy)-1,2,5-thiadiazole Chemical compound CC(C)OCCOC1=NSN=C1C1=CCCN(C)C1 KVMADAPPEILLFV-UHFFFAOYSA-N 0.000 description 1
- UUUCYXKEKJRLQC-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(3,3,3-trifluoropropylsulfanyl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCC(F)(F)F UUUCYXKEKJRLQC-UHFFFAOYSA-N 0.000 description 1
- RBJVMENWQAVDNW-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(3-methylpent-4-enoxy)-1,2,5-thiadiazole Chemical compound C=CC(C)CCOC1=NSN=C1C1=CCCN(C)C1 RBJVMENWQAVDNW-UHFFFAOYSA-N 0.000 description 1
- XGGPVZQHQTXACT-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(3-methylpentoxy)-1,2,5-thiadiazole Chemical compound CCC(C)CCOC1=NSN=C1C1=CCCN(C)C1 XGGPVZQHQTXACT-UHFFFAOYSA-N 0.000 description 1
- UKVJUROELMQVGS-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(3-phenylbutoxy)-1,2,5-thiadiazole Chemical compound C=1C=CC=CC=1C(C)CCOC1=NSN=C1C1=CCCN(C)C1 UKVJUROELMQVGS-UHFFFAOYSA-N 0.000 description 1
- GEHAYIPJIXUMSQ-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(3-phenylpropoxy)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCC1=CC=CC=C1 GEHAYIPJIXUMSQ-UHFFFAOYSA-N 0.000 description 1
- YPIJABWYOZAYLQ-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(3-phenylpropylsulfanyl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCC1=CC=CC=C1 YPIJABWYOZAYLQ-UHFFFAOYSA-N 0.000 description 1
- VIPKZQQVHOYTDG-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(4,4,4-trifluorobutoxy)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCC(F)(F)F VIPKZQQVHOYTDG-UHFFFAOYSA-N 0.000 description 1
- WOEVKWIBOLETCN-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(4,4,4-trifluorobutylsulfanyl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCC(F)(F)F WOEVKWIBOLETCN-UHFFFAOYSA-N 0.000 description 1
- FYRNNSGKTNDUDO-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(4-methylhexoxy)-1,2,5-thiadiazole Chemical compound CCC(C)CCCOC1=NSN=C1C1=CCCN(C)C1 FYRNNSGKTNDUDO-UHFFFAOYSA-N 0.000 description 1
- BBFYFLUXOWMIDL-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(4-methylpentoxy)-1,2,5-thiadiazole Chemical compound CC(C)CCCOC1=NSN=C1C1=CCCN(C)C1 BBFYFLUXOWMIDL-UHFFFAOYSA-N 0.000 description 1
- LZHVQIFAWOTJLN-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(4-methylpentylsulfanyl)-1,2,5-thiadiazole Chemical compound CC(C)CCCSC1=NSN=C1C1=CCCN(C)C1 LZHVQIFAWOTJLN-UHFFFAOYSA-N 0.000 description 1
- OQHYBJMGEORIMC-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(4-phenylsulfanylbutylsulfanyl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCCSC1=CC=CC=C1 OQHYBJMGEORIMC-UHFFFAOYSA-N 0.000 description 1
- OHIOWBZOZYBZFY-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(5,5,5-trifluoropentylsulfanyl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCCC(F)(F)F OHIOWBZOZYBZFY-UHFFFAOYSA-N 0.000 description 1
- PIDJSLXGEGWZNA-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(5-methylhexoxy)-1,2,5-thiadiazole Chemical compound CC(C)CCCCOC1=NSN=C1C1=CCCN(C)C1 PIDJSLXGEGWZNA-UHFFFAOYSA-N 0.000 description 1
- JJTRWMUPRMUTDP-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-(6,6,6-trifluorohexoxy)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCCCC(F)(F)F JJTRWMUPRMUTDP-UHFFFAOYSA-N 0.000 description 1
- YDCIKDNWWKYIFL-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-[2-(2-methylpropylsulfanyl)ethoxy]-1,2,5-thiadiazole Chemical compound CC(C)CSCCOC1=NSN=C1C1=CCCN(C)C1 YDCIKDNWWKYIFL-UHFFFAOYSA-N 0.000 description 1
- UHUQVNCBWRGRGZ-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-[3-(2-methylphenyl)propoxy]-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCC1=CC=CC=C1C UHUQVNCBWRGRGZ-UHFFFAOYSA-N 0.000 description 1
- SGQUZSYRIZOLFQ-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-methylsulfanyl-1,2,5-thiadiazole Chemical compound CSC1=NSN=C1C1=CCCN(C)C1 SGQUZSYRIZOLFQ-UHFFFAOYSA-N 0.000 description 1
- YDEGIPBYKABSOG-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-oct-7-enylsulfanyl-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCCCCC=C YDEGIPBYKABSOG-UHFFFAOYSA-N 0.000 description 1
- IVZSSVVWNPQOIC-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-octoxy-1,2,5-thiadiazole Chemical compound CCCCCCCCOC1=NSN=C1C1=CCCN(C)C1 IVZSSVVWNPQOIC-UHFFFAOYSA-N 0.000 description 1
- KPLAPEPQTMEDIW-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-octylsulfanyl-1,2,5-thiadiazole Chemical compound CCCCCCCCSC1=NSN=C1C1=CCCN(C)C1 KPLAPEPQTMEDIW-UHFFFAOYSA-N 0.000 description 1
- YUPHTAZBBZCCPA-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-pent-3-ynoxy-1,2,5-thiadiazole Chemical compound CC#CCCOC1=NSN=C1C1=CCCN(C)C1 YUPHTAZBBZCCPA-UHFFFAOYSA-N 0.000 description 1
- LFDTVFUWANUZHD-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-pent-4-enoxy-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCC=C LFDTVFUWANUZHD-UHFFFAOYSA-N 0.000 description 1
- DLDKRLAHQVRXPU-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-pent-4-enylsulfanyl-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCC=C DLDKRLAHQVRXPU-UHFFFAOYSA-N 0.000 description 1
- YNRVQZRAOVQAAH-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-pent-4-ynylsulfanyl-1,2,5-oxadiazole Chemical compound C1N(C)CCC=C1C1=NON=C1SCCCC#C YNRVQZRAOVQAAH-UHFFFAOYSA-N 0.000 description 1
- NVHWAOHWBPPEFZ-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-pent-4-ynylsulfanyl-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCC#C NVHWAOHWBPPEFZ-UHFFFAOYSA-N 0.000 description 1
- JJWIFEIHNQNTLK-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-pentoxy-1,2,5-thiadiazole Chemical compound CCCCCOC1=NSN=C1C1=CCCN(C)C1 JJWIFEIHNQNTLK-UHFFFAOYSA-N 0.000 description 1
- ZDVCEUIRGYHXFK-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-pentylsulfanyl-1,2,5-oxadiazole Chemical compound CCCCCSC1=NON=C1C1=CCCN(C)C1 ZDVCEUIRGYHXFK-UHFFFAOYSA-N 0.000 description 1
- LRTWCQHCJKYNPS-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-pentylsulfanyl-1,2,5-thiadiazole Chemical compound CCCCCSC1=NSN=C1C1=CCCN(C)C1 LRTWCQHCJKYNPS-UHFFFAOYSA-N 0.000 description 1
- TXHQPJHKDCHFPR-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-prop-2-enoxy-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCC=C TXHQPJHKDCHFPR-UHFFFAOYSA-N 0.000 description 1
- FPWMSVQHQLDGOT-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-prop-2-ynoxy-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCC#C FPWMSVQHQLDGOT-UHFFFAOYSA-N 0.000 description 1
- HNGVRLJGXVLFSN-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-propan-2-yloxy-1,2,5-thiadiazole Chemical compound CC(C)OC1=NSN=C1C1=CCCN(C)C1 HNGVRLJGXVLFSN-UHFFFAOYSA-N 0.000 description 1
- VGRPVZDIAOGCMM-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-propoxy-1,2,5-thiadiazole Chemical compound CCCOC1=NSN=C1C1=CCCN(C)C1 VGRPVZDIAOGCMM-UHFFFAOYSA-N 0.000 description 1
- RZCFZRYCCGLCRP-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-4-propylsulfanyl-1,2,5-thiadiazole Chemical compound CCCSC1=NSN=C1C1=CCCN(C)C1 RZCFZRYCCGLCRP-UHFFFAOYSA-N 0.000 description 1
- YJNOSANRLXEFOG-UHFFFAOYSA-N 3-(2,3-dimethylpentoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCC(C)C(C)COC1=NSN=C1C1=CCCN(C)C1 YJNOSANRLXEFOG-UHFFFAOYSA-N 0.000 description 1
- FNXHBSDAVXQJJK-UHFFFAOYSA-N 3-(2-benzylsulfanylethoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCSCC1=CC=CC=C1 FNXHBSDAVXQJJK-UHFFFAOYSA-N 0.000 description 1
- KVBJHCQENAISKB-UHFFFAOYSA-N 3-(2-butoxyethoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCOCCOC1=NSN=C1C1=CCCN(C)C1 KVBJHCQENAISKB-UHFFFAOYSA-N 0.000 description 1
- NFOGXKGGTGAWMK-UHFFFAOYSA-N 3-(2-cyclohexylethoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCC1CCCCC1 NFOGXKGGTGAWMK-UHFFFAOYSA-N 0.000 description 1
- VRPATFPEVNNLOT-UHFFFAOYSA-N 3-(2-ethoxyethoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCOCCOC1=NSN=C1C1=CCCN(C)C1 VRPATFPEVNNLOT-UHFFFAOYSA-N 0.000 description 1
- BEZLKUWADBJWRX-UHFFFAOYSA-N 3-(2-ethylbutylsulfanyl)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCC(CC)CSC1=NSN=C1C1=CCCN(C)C1 BEZLKUWADBJWRX-UHFFFAOYSA-N 0.000 description 1
- AEVYVHBBBDPZBF-UHFFFAOYSA-N 3-(2-methoxyethoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound COCCOC1=NSN=C1C1=CCCN(C)C1 AEVYVHBBBDPZBF-UHFFFAOYSA-N 0.000 description 1
- AMVDCWMTBOYBGS-UHFFFAOYSA-N 3-(2-phenoxyethylsulfanyl)-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole Chemical compound C=1C=CC=CC=1OCCSC1=NSN=C1C1=CCCNC1 AMVDCWMTBOYBGS-UHFFFAOYSA-N 0.000 description 1
- HHHPIPJAQMLYIW-UHFFFAOYSA-N 3-(3-chloropropylsulfanyl)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCCl HHHPIPJAQMLYIW-UHFFFAOYSA-N 0.000 description 1
- XWKLTXNZAXFRFO-UHFFFAOYSA-N 3-(3-cyclohexylpropoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCC1CCCCC1 XWKLTXNZAXFRFO-UHFFFAOYSA-N 0.000 description 1
- VBGHUUUMKDBJTO-UHFFFAOYSA-N 3-(3-cyclopentylpropoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCC1CCCC1 VBGHUUUMKDBJTO-UHFFFAOYSA-N 0.000 description 1
- SIPUNMHDPPDLET-UHFFFAOYSA-N 3-(3-cyclopropylpropoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCC1CC1 SIPUNMHDPPDLET-UHFFFAOYSA-N 0.000 description 1
- MQSWNYJTHPVGSX-UHFFFAOYSA-N 3-(3-methylbut-2-enoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCC=C(C)C MQSWNYJTHPVGSX-UHFFFAOYSA-N 0.000 description 1
- LSSKYJSJTOVEPJ-UHFFFAOYSA-N 3-(3-methylbutoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CC(C)CCOC1=NSN=C1C1=CCCN(C)C1 LSSKYJSJTOVEPJ-UHFFFAOYSA-N 0.000 description 1
- FEPNFYAMAPTNCJ-UHFFFAOYSA-N 3-(4-chlorobutylsulfanyl)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCCCl FEPNFYAMAPTNCJ-UHFFFAOYSA-N 0.000 description 1
- MCKCKMPHVRIGGZ-UHFFFAOYSA-N 3-(6-chlorohexylsulfanyl)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCCCCCl MCKCKMPHVRIGGZ-UHFFFAOYSA-N 0.000 description 1
- HDJWOXFOVDRNKD-UHFFFAOYSA-N 3-(azetidin-3-yloxy)-4-butoxy-1,2,5-thiadiazole Chemical compound CCCCOC1=NSN=C1OC1CNC1 HDJWOXFOVDRNKD-UHFFFAOYSA-N 0.000 description 1
- RPBRMUWJADZHQC-UHFFFAOYSA-N 3-(azetidin-3-yloxy)-4-butylsulfanyl-1,2,5-oxadiazole Chemical compound CCCCSC1=NON=C1OC1CNC1 RPBRMUWJADZHQC-UHFFFAOYSA-N 0.000 description 1
- DYWGQNMNDMGOMW-UHFFFAOYSA-N 3-(azetidin-3-yloxy)-4-butylsulfanyl-1,2,5-thiadiazole Chemical compound CCCCSC1=NSN=C1OC1CNC1 DYWGQNMNDMGOMW-UHFFFAOYSA-N 0.000 description 1
- POVIXWUWYJKDHJ-UHFFFAOYSA-N 3-(cyclohex-3-en-1-ylmethoxy)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCC1CC=CCC1 POVIXWUWYJKDHJ-UHFFFAOYSA-N 0.000 description 1
- YLFHBGQFBWRVPA-UHFFFAOYSA-N 3-(cyclopropylmethylsulfanyl)-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCC1CC1 YLFHBGQFBWRVPA-UHFFFAOYSA-N 0.000 description 1
- BMYDPMQCNCBXCO-UHFFFAOYSA-N 3-[(2-methylcyclopropyl)methoxy]-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CC1CC1COC1=NSN=C1C1=CCCN(C)C1 BMYDPMQCNCBXCO-UHFFFAOYSA-N 0.000 description 1
- WCQLOOSYXJXWDA-UHFFFAOYSA-N 3-[(4-butylphenyl)methoxy]-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1=CC(CCCC)=CC=C1COC1=NSN=C1C1=CCCN(C)C1 WCQLOOSYXJXWDA-UHFFFAOYSA-N 0.000 description 1
- JXUXYRMUFTZRGM-UHFFFAOYSA-N 3-[(4-ethylphenyl)methoxy]-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1=CC(CC)=CC=C1COC1=NSN=C1C1=CCCN(C)C1 JXUXYRMUFTZRGM-UHFFFAOYSA-N 0.000 description 1
- FBBHRBAIOINPJS-UHFFFAOYSA-N 3-[2-(2-butoxyethoxy)ethoxy]-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCOCCOCCOC1=NSN=C1C1=CCCN(C)C1 FBBHRBAIOINPJS-UHFFFAOYSA-N 0.000 description 1
- ADQSUMYTVDGKGQ-UHFFFAOYSA-N 3-[2-(2-methoxyethoxy)ethoxy]-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound COCCOCCOC1=NSN=C1C1=CCCN(C)C1 ADQSUMYTVDGKGQ-UHFFFAOYSA-N 0.000 description 1
- WHSSJHPCHABIAB-UHFFFAOYSA-N 3-[3-(2,5-dimethylphenyl)propoxy]-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCC1=CC(C)=CC=C1C WHSSJHPCHABIAB-UHFFFAOYSA-N 0.000 description 1
- BSQFUMDFYIRACV-UHFFFAOYSA-N 3-[3-(3,4-dichlorophenyl)propoxy]-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCC1=CC=C(Cl)C(Cl)=C1 BSQFUMDFYIRACV-UHFFFAOYSA-N 0.000 description 1
- WKBGOWZILNQEEB-UHFFFAOYSA-N 3-[3-(4-chlorophenyl)propoxy]-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCC1=CC=C(Cl)C=C1 WKBGOWZILNQEEB-UHFFFAOYSA-N 0.000 description 1
- AIZRYKWHKRTRAC-UHFFFAOYSA-N 3-[3-(4-fluorophenyl)propoxy]-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCC1=CC=C(F)C=C1 AIZRYKWHKRTRAC-UHFFFAOYSA-N 0.000 description 1
- HJMGHTQVTGUYDG-UHFFFAOYSA-N 3-[3-(4-methoxyphenyl)propoxy]-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1=CC(OC)=CC=C1CCCOC1=NSN=C1C1=CCCN(C)C1 HJMGHTQVTGUYDG-UHFFFAOYSA-N 0.000 description 1
- MDJBIVIKJLJSNO-UHFFFAOYSA-N 3-[4,4-bis(4-fluorophenyl)butylsulfanyl]-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 MDJBIVIKJLJSNO-UHFFFAOYSA-N 0.000 description 1
- NWUNHTNQYCHZGQ-UHFFFAOYSA-N 3-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]oxy]propan-1-ol Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCO NWUNHTNQYCHZGQ-UHFFFAOYSA-N 0.000 description 1
- WDSQFIRIQIHCJH-UHFFFAOYSA-N 3-but-2-ynoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CC#CCOC1=NSN=C1C1=CCCN(C)C1 WDSQFIRIQIHCJH-UHFFFAOYSA-N 0.000 description 1
- JWQXAVWRBNMIIB-UHFFFAOYSA-N 3-but-3-enoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCC=C JWQXAVWRBNMIIB-UHFFFAOYSA-N 0.000 description 1
- ZPCNLMZMINCFAK-UHFFFAOYSA-N 3-but-3-enylsulfanyl-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCC=C ZPCNLMZMINCFAK-UHFFFAOYSA-N 0.000 description 1
- CZXZMADCZMEETO-UHFFFAOYSA-N 3-butoxy-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCOC1=NSN=C1C1=CCCNC1 CZXZMADCZMEETO-UHFFFAOYSA-N 0.000 description 1
- YGJVFXOACAMRAX-UHFFFAOYSA-N 3-butoxy-4-(1,2-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCOC1=NSN=C1C1=CCC(C)N(C)C1 YGJVFXOACAMRAX-UHFFFAOYSA-N 0.000 description 1
- MHWUWCDFTFBXNV-UHFFFAOYSA-N 3-butoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCOC1=NSN=C1C1=CCCN(C)C1 MHWUWCDFTFBXNV-UHFFFAOYSA-N 0.000 description 1
- ZRGMLQRNGIQNSF-JTQLQIEISA-N 3-butoxy-4-[[(2s)-1-methylpyrrolidin-2-yl]methoxy]-1,2,5-thiadiazole Chemical compound CCCCOC1=NSN=C1OC[C@H]1N(C)CCC1 ZRGMLQRNGIQNSF-JTQLQIEISA-N 0.000 description 1
- BNHOGNJHZDZCIX-VIFPVBQESA-N 3-butoxy-4-[[(2s)-pyrrolidin-2-yl]methoxy]-1,2,5-thiadiazole Chemical compound CCCCOC1=NSN=C1OC[C@H]1NCCC1 BNHOGNJHZDZCIX-VIFPVBQESA-N 0.000 description 1
- QZGJDVQMJUMOQL-UHFFFAOYSA-N 3-butylsulfanyl-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCSC1=NSN=C1C1=CCCNC1 QZGJDVQMJUMOQL-UHFFFAOYSA-N 0.000 description 1
- FTDTYVQTUSEPTK-UHFFFAOYSA-N 3-butylsulfanyl-4-(1,2-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCSC1=NSN=C1C1=CCC(C)N(C)C1 FTDTYVQTUSEPTK-UHFFFAOYSA-N 0.000 description 1
- SFXHHGRYNXLPKT-UHFFFAOYSA-N 3-butylsulfanyl-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCSC1=NSN=C1C1=CCCN(C)C1 SFXHHGRYNXLPKT-UHFFFAOYSA-N 0.000 description 1
- LXKTVNNJNWNLTO-UHFFFAOYSA-N 3-butylsulfanyl-4-(1-methylpiperidin-4-yl)oxy-1,2,5-thiadiazole Chemical compound CCCCSC1=NSN=C1OC1CCN(C)CC1 LXKTVNNJNWNLTO-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- NMVSXIDOFUZQJQ-UHFFFAOYSA-N 3-cyclopentylsulfanyl-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1SC1CCCC1 NMVSXIDOFUZQJQ-UHFFFAOYSA-N 0.000 description 1
- WCJPIRVYBXBRCS-UHFFFAOYSA-N 3-ethoxy-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCOC1=NSN=C1C1=CCCNC1 WCJPIRVYBXBRCS-UHFFFAOYSA-N 0.000 description 1
- QAQIVDUXGFXBJE-UHFFFAOYSA-N 3-ethoxy-4-(1-ethyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCOC1=NSN=C1C1=CCCN(CC)C1 QAQIVDUXGFXBJE-UHFFFAOYSA-N 0.000 description 1
- FVFYCQYZPZLAQO-UHFFFAOYSA-N 3-ethoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCOC1=NSN=C1C1=CCCN(C)C1 FVFYCQYZPZLAQO-UHFFFAOYSA-N 0.000 description 1
- CCCGPQHDOFLOLZ-UHFFFAOYSA-N 3-ethylsulfanyl-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCSC1=NSN=C1C1=CCCNC1 CCCGPQHDOFLOLZ-UHFFFAOYSA-N 0.000 description 1
- GHXWVRUTFAIAPR-UHFFFAOYSA-N 3-ethylsulfanyl-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCSC1=NSN=C1C1=CCCN(C)C1 GHXWVRUTFAIAPR-UHFFFAOYSA-N 0.000 description 1
- XGWJINGLDATYHE-UHFFFAOYSA-N 3-heptan-2-yloxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCCC(C)OC1=NSN=C1C1=CCCN(C)C1 XGWJINGLDATYHE-UHFFFAOYSA-N 0.000 description 1
- XNHZKFQJIBIRBV-UHFFFAOYSA-N 3-heptoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCCCCOC1=NSN=C1C1=CCCN(C)C1 XNHZKFQJIBIRBV-UHFFFAOYSA-N 0.000 description 1
- CPVSIMRIVUSDCU-UHFFFAOYSA-N 3-heptylsulfanyl-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCCCCSC1=NSN=C1C1=CCCN(C)C1 CPVSIMRIVUSDCU-UHFFFAOYSA-N 0.000 description 1
- OPACENDCWSVMKV-UHFFFAOYSA-N 3-hex-3-ynoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-oxadiazole Chemical compound CCC#CCCOC1=NON=C1C1=CCCN(C)C1 OPACENDCWSVMKV-UHFFFAOYSA-N 0.000 description 1
- WONKJMLJPPLVKS-UHFFFAOYSA-N 3-hex-3-ynoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCC#CCCOC1=NSN=C1C1=CCCN(C)C1 WONKJMLJPPLVKS-UHFFFAOYSA-N 0.000 description 1
- PNKPOENNRUYUFU-UHFFFAOYSA-N 3-hex-4-enoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CC=CCCCOC1=NSN=C1C1=CCCN(C)C1 PNKPOENNRUYUFU-UHFFFAOYSA-N 0.000 description 1
- GIJLUDKMLHVJIP-UHFFFAOYSA-N 3-hex-5-enoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCCC=C GIJLUDKMLHVJIP-UHFFFAOYSA-N 0.000 description 1
- ONACTFAOHURRPY-UHFFFAOYSA-N 3-hex-5-ynoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCCC#C ONACTFAOHURRPY-UHFFFAOYSA-N 0.000 description 1
- QJAUKZXBWHDAIU-UHFFFAOYSA-N 3-hexan-2-yloxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCC(C)OC1=NSN=C1C1=CCCN(C)C1 QJAUKZXBWHDAIU-UHFFFAOYSA-N 0.000 description 1
- DGXQYFBISZBJLQ-UHFFFAOYSA-N 3-hexan-3-yloxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCC(CC)OC1=NSN=C1C1=CCCN(C)C1 DGXQYFBISZBJLQ-UHFFFAOYSA-N 0.000 description 1
- ZJOUESNWCLASJP-UHFFFAOYSA-N 3-hexoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCCCOC1=NSN=C1C1=CCCN(C)C1 ZJOUESNWCLASJP-UHFFFAOYSA-N 0.000 description 1
- NLBRMIWFUVXSRS-UHFFFAOYSA-N 3-hexoxy-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole Chemical compound CCCCCCOC1=NSN=C1C1=CC=C[N+](C)=C1 NLBRMIWFUVXSRS-UHFFFAOYSA-N 0.000 description 1
- PLDTVIHYDHJMEQ-UHFFFAOYSA-M 3-hexoxy-4-(1-methylpyridin-1-ium-3-yl)-1,2,5-thiadiazole;iodide Chemical compound [I-].CCCCCCOC1=NSN=C1C1=CC=C[N+](C)=C1 PLDTVIHYDHJMEQ-UHFFFAOYSA-M 0.000 description 1
- MUCMEIJIIUNURR-UHFFFAOYSA-N 3-hexylsulfanyl-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-oxadiazole Chemical compound CCCCCCSC1=NON=C1C1=CCCN(C)C1 MUCMEIJIIUNURR-UHFFFAOYSA-N 0.000 description 1
- PLAIJYWERMWGQR-UHFFFAOYSA-N 3-pent-4-ynylsulfanyl-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole Chemical compound C#CCCCSC1=NSN=C1C1=CCCNC1 PLAIJYWERMWGQR-UHFFFAOYSA-N 0.000 description 1
- GKJOESOKTSYJRW-UHFFFAOYSA-N 3-pentylsulfanyl-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCCCSC1=NSN=C1C1=CCCNC1 GKJOESOKTSYJRW-UHFFFAOYSA-N 0.000 description 1
- OGJLVOAXQBHUDJ-UHFFFAOYSA-N 3-propylsulfanyl-4-(1,2,3,6-tetrahydropyridin-5-yl)-1,2,5-thiadiazole Chemical compound CCCSC1=NSN=C1C1=CCCNC1 OGJLVOAXQBHUDJ-UHFFFAOYSA-N 0.000 description 1
- AHSTZHYPZOUXKG-UHFFFAOYSA-N 4-[[4-(1,2-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanylmethyl]benzonitrile Chemical compound C1N(C)C(C)CC=C1C1=NSN=C1SCC1=CC=C(C#N)C=C1 AHSTZHYPZOUXKG-UHFFFAOYSA-N 0.000 description 1
- KVTBPDAUQZIPQQ-UHFFFAOYSA-N 4-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]oxy]butanoic acid Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCC(O)=O KVTBPDAUQZIPQQ-UHFFFAOYSA-N 0.000 description 1
- CATBFFWKQFTMIW-UHFFFAOYSA-N 4-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanyl]butane-1-thiol Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCCS CATBFFWKQFTMIW-UHFFFAOYSA-N 0.000 description 1
- WJJIWLRMLCNJRC-UHFFFAOYSA-N 4-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanyl]butanenitrile Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCC#N WJJIWLRMLCNJRC-UHFFFAOYSA-N 0.000 description 1
- SNEZVMXABYBZPG-UHFFFAOYSA-N 4-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanyl]butanoic acid Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCC(O)=O SNEZVMXABYBZPG-UHFFFAOYSA-N 0.000 description 1
- NLERVEIQGXQREW-UHFFFAOYSA-N 4-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanylmethyl]benzonitrile Chemical compound C1N(C)CCC=C1C1=NSN=C1SCC1=CC=C(C#N)C=C1 NLERVEIQGXQREW-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- JTSQBBBLULOZJC-UHFFFAOYSA-N 5-[[4-(1,2-dimethyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanyl]pentanenitrile Chemical compound C1N(C)C(C)CC=C1C1=NSN=C1SCCCCC#N JTSQBBBLULOZJC-UHFFFAOYSA-N 0.000 description 1
- LXBFOGJHOZLEFK-UHFFFAOYSA-N 5-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanyl]pentane-1-thiol Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCCCS LXBFOGJHOZLEFK-UHFFFAOYSA-N 0.000 description 1
- BQWINSBQAYHHGH-UHFFFAOYSA-N 5-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanyl]pentanenitrile Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCCC#N BQWINSBQAYHHGH-UHFFFAOYSA-N 0.000 description 1
- GEHRSERUQRFUFW-UHFFFAOYSA-N 5-ethylhex-2-ynedioic acid Chemical compound CCC(C(O)=O)CC#CC(O)=O GEHRSERUQRFUFW-UHFFFAOYSA-N 0.000 description 1
- LBRXWIVYANXEFH-UHFFFAOYSA-N 6-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]oxy]hexan-2-ol Chemical compound CC(O)CCCCOC1=NSN=C1C1=CCCN(C)C1 LBRXWIVYANXEFH-UHFFFAOYSA-N 0.000 description 1
- UOTOPEAPMMAEAR-UHFFFAOYSA-N 6-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanyl]hexane-1-thiol Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCCCCS UOTOPEAPMMAEAR-UHFFFAOYSA-N 0.000 description 1
- AHDWZSLRVONYEW-UHFFFAOYSA-N 6-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanyl]hexanenitrile Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCCCC#N AHDWZSLRVONYEW-UHFFFAOYSA-N 0.000 description 1
- VFWBYACRVMJLBH-UHFFFAOYSA-N 6-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanyl]hexanoic acid Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCCCC(O)=O VFWBYACRVMJLBH-UHFFFAOYSA-N 0.000 description 1
- DYJSZYZSPNVGDV-UHFFFAOYSA-N 8-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanyl]octan-1-ol Chemical compound C1N(C)CCC=C1C1=NSN=C1SCCCCCCCCO DYJSZYZSPNVGDV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000021465 Brief psychotic disease Diseases 0.000 description 1
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 208000030988 Schizoid Personality disease Diseases 0.000 description 1
- 208000036754 Schizophrenia, catatonic type Diseases 0.000 description 1
- 208000036753 Schizophrenia, disorganised type Diseases 0.000 description 1
- 208000036752 Schizophrenia, paranoid type Diseases 0.000 description 1
- 208000036750 Schizophrenia, residual type Diseases 0.000 description 1
- 208000019568 Shared Paranoid disease Diseases 0.000 description 1
- 208000028810 Shared psychotic disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 description 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 229960000276 acetophenazine Drugs 0.000 description 1
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 description 1
- 229960000910 bethanechol Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229960004037 bromperidol Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- PXJJSXABGXMUSU-UHFFFAOYSA-N disulfur dichloride Chemical compound ClSSCl PXJJSXABGXMUSU-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- KZZCAMNMPFPFFL-UHFFFAOYSA-N ethyl 2-ethyl-4-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanyl]butanoate Chemical compound CCOC(=O)C(CC)CCSC1=NSN=C1C1=CCCN(C)C1 KZZCAMNMPFPFFL-UHFFFAOYSA-N 0.000 description 1
- QSFLDIAOSFPUBX-UHFFFAOYSA-N ethyl 4-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]sulfanyl]butanoate Chemical compound CCOC(=O)CCCSC1=NSN=C1C1=CCCN(C)C1 QSFLDIAOSFPUBX-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000300 mesoridazine Drugs 0.000 description 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- YMMXHEYLRHNXAB-RMKNXTFCSA-N milameline Chemical compound CO\N=C\C1=CCCN(C)C1 YMMXHEYLRHNXAB-RMKNXTFCSA-N 0.000 description 1
- 229950004373 milameline Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- GDMCUQHKQDZGJD-UHFFFAOYSA-N n-[2-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]oxy]ethyl]acetamide Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCNC(C)=O GDMCUQHKQDZGJD-UHFFFAOYSA-N 0.000 description 1
- UPEVSONWUMAQLA-UHFFFAOYSA-N n-[2-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]oxy]ethyl]propanamide Chemical compound CCC(=O)NCCOC1=NSN=C1C1=CCCN(C)C1 UPEVSONWUMAQLA-UHFFFAOYSA-N 0.000 description 1
- GVHXHXWCHUIGOO-UHFFFAOYSA-N n-[6-[[4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazol-3-yl]oxy]hexyl]acetamide Chemical compound C1N(C)CCC=C1C1=NSN=C1OCCCCCCNC(C)=O GVHXHXWCHUIGOO-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229950004193 perospirone Drugs 0.000 description 1
- GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- 229960004265 piperacetazine Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012066 reaction slurry Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- IQWCBYSUUOFOMF-QTLFRQQHSA-N sabcomeline Chemical compound C1CC2[C@@H](C(/C#N)=N/OC)CN1CC2 IQWCBYSUUOFOMF-QTLFRQQHSA-N 0.000 description 1
- 229950000425 sabcomeline Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- FKJIJBSJQSMPTI-CAOXKPNISA-M sodium;(4r)-4-[(5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C FKJIJBSJQSMPTI-CAOXKPNISA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- XVFJONKUSLSKSW-JTQLQIEISA-N talsaclidine Chemical compound C1CC2[C@@H](OCC#C)CN1CC2 XVFJONKUSLSKSW-JTQLQIEISA-N 0.000 description 1
- 229950001645 talsaclidine Drugs 0.000 description 1
- XUHMGFKQBWZWPO-UHFFFAOYSA-N tazomeline Chemical compound CCCCCCSC1=NSN=C1C1=CCCN(C)C1 XUHMGFKQBWZWPO-UHFFFAOYSA-N 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004728 thiopropazate Drugs 0.000 description 1
- AIUHRQHVWSUTGJ-UHFFFAOYSA-N thiopropazate Chemical compound C1CN(CCOC(=O)C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 AIUHRQHVWSUTGJ-UHFFFAOYSA-N 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960005013 tiotixene Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 229960003904 triflupromazine Drugs 0.000 description 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- 229960004496 zotepine Drugs 0.000 description 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne une thérapie de combinaison comprenant un premier composant qui est un antipsychotique typique ou atypique et un second composant qui est un agoniste muscarinique. Cette thérapie est destinée au traitement des psychoses et d'autres troubles.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21551600P | 2000-06-30 | 2000-06-30 | |
| US60/215,516 | 2000-06-30 | ||
| PCT/US2001/014863 WO2002003684A2 (fr) | 2000-06-30 | 2001-06-18 | Therapie de combinaison pour le traitement des psychoses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2411386A1 true CA2411386A1 (fr) | 2002-01-10 |
Family
ID=22803282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002411386A Abandoned CA2411386A1 (fr) | 2000-06-30 | 2001-06-18 | Therapie de combinaison pour le traitement des psychoses |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1316203A2 (fr) |
| JP (1) | JP2004502655A (fr) |
| AU (1) | AU2001268055A1 (fr) |
| CA (1) | CA2411386A1 (fr) |
| WO (1) | WO2002003684A2 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0428180D0 (en) * | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Combination therapy |
| GB0428170D0 (en) * | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Mono and Combination Therapy |
| CA2620333A1 (fr) * | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenese par modulation du recepteur muscarinique |
| PL3061821T3 (pl) * | 2009-07-22 | 2020-01-31 | PureTech Health LLC | Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| PL3134386T3 (pl) | 2014-04-23 | 2020-11-16 | Takeda Pharmaceutical Company Limited | Pochodne izoindolin-1-onu jako dodatnia aktywność allosterycznego modulatora cholinergicznego receptora muskarynowego m1 do leczenia choroby alzheimera |
| TN2017000508A1 (en) | 2015-06-26 | 2019-04-12 | Takeda Pharmaceuticals Co | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| JP6787913B2 (ja) | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| JP7096441B2 (ja) | 2018-09-28 | 2022-07-05 | カルナ セラピューティックス，インコーポレイテッド | ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法 |
| EP4091607A1 (fr) * | 2021-05-18 | 2022-11-23 | Karuna Therapeutics, Inc. | Procédés de traitement de troubles du système nerveux central par l'activateur du récepteur muscarinique xanoméline et des antipsychotiques |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
-
2001
- 2001-06-18 EP EP01945949A patent/EP1316203A2/fr not_active Withdrawn
- 2001-06-18 AU AU2001268055A patent/AU2001268055A1/en not_active Abandoned
- 2001-06-18 CA CA002411386A patent/CA2411386A1/fr not_active Abandoned
- 2001-06-18 JP JP2002507636A patent/JP2004502655A/ja not_active Withdrawn
- 2001-06-18 WO PCT/US2001/014863 patent/WO2002003684A2/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001268055A1 (en) | 2002-01-14 |
| WO2002003684A2 (fr) | 2002-01-10 |
| EP1316203A2 (fr) | 2003-06-04 |
| JP2004502655A (ja) | 2004-01-29 |
| WO2002003684A3 (fr) | 2003-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5739151A (en) | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride | |
| CA2332814C (fr) | Therapie combinee de traitement de la depression resistante | |
| US20040023951A1 (en) | Combination therapy for treatment of psychoses | |
| IL126203A (en) | A synergistic painkiller that contains olenzapine and another painkiller | |
| NZ513966A (en) | Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists | |
| EP0709094B1 (fr) | Tétrahydropyridine oxadiazole ou thiadiazole pour traiter l'anxiété | |
| CA2167004C (fr) | Agent pour le traitement de troubles mentaux associes a des troubles cerebrovasculaires | |
| CA2411386A1 (fr) | Therapie de combinaison pour le traitement des psychoses | |
| MX2007011436A (es) | Ligando del receptor nicotinico neuronal 7 y composiciones antipsicoticas. | |
| US20090258084A1 (en) | Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia | |
| US6297262B1 (en) | Treatment of schizophrenia and psychosis | |
| EP1838310A1 (fr) | Combinaison de la sabcoméline avec un agent neuroleptique dans le traitement de troubles psychotiques | |
| US20090318414A1 (en) | Mono and Combination Therapy with M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Prodromal Syndrome | |
| US6147093A (en) | Methods for treating gastroesophageal reflux disease | |
| EP0738515A1 (fr) | Traitement du sevrage de la nicotine | |
| EP1007050B1 (fr) | L'olanzapine dans le traitement de la pharmacodependance | |
| EP0709093A2 (fr) | Utilisation d'une oxadiazole ou thiadiazole azabicyclique dans le traitement de l'anxiété | |
| US5750541A (en) | Method of treating schizophrenia | |
| US5545638A (en) | Method of treating gastrointestinal motility disorders | |
| Ninan et al. | Antagonism by pimozide of olanzapine‐induced hypothermia | |
| MXPA00011353A (es) | Uso de olanzapida en combinación con fluoxetina para terapia de la depresión refractaria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |